NT-0796 is under clinical development by NodThera and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NT-0796’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NT-0796 overview
NT-0796 is under development for the treatment of inflammation in obese participants at risk of cardiovascular disease, atherosclerosis, obesity and Parkinson’s disease. They cross the blood-brain barrier and act by targeting NLRP3 inflammasomes. It is administered through oral route.
NodThera overview
NodThera, a subsidiary of NodThera Ltd, is a biotechnology company that discovers and develops treatments for chronic inflammation. It is investigating its lead product candidate NT-0796 against peripheral and neuroinflammatory diseases. The company is also evaluating NT-0249, a peripherally restricted NLRP3 inflammasome inhibitor to develop a low-dose therapy addressing chronic inflammatory diseases of the body. NodThera’s approach focuses on delivering advances in potency, tissue and brain penetration and chemical structural diversity. It operates with additional offices in Seattle, the US, and Cambridge, the UK. NodThera is headquartered in Lexington, Massachusetts, the US.
For a complete picture of NT-0796’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
